ArticleDrug safety2023

Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021.

Sharon C M Essink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.